An observational study in Multiple Sclerosis, sponsored by Cairo University. Not yet recruiting. Open to participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Cairo University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Multiple Sclerosis by Cairo University — 8 open to participants now, 10 under way, none of them phase 3. Multiple Sclerosis · Cairo University.
Among the 26 studies in Multiple Sclerosis by Cairo University, this one is one of 4 that started in 2026, is one of 6 observational ones, and was the 26th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →8 of the 26 studies in Multiple Sclerosis by Cairo University are open now, in 1 country. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 20–35
Cairo University · Sites in Egypt
Ages 20–45
Cairo University · Sites in Egypt
Ages 20–50
Cairo University
Ages 25–40
Cairo University · Sites in Egypt
Ages 20–50
By country, each count listing its studies:
Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 20 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 94 is close to the median of 100 across 971 observational studies indexed under Multiple Sclerosis.
Median enrollment 40 across the 20 interventional studies, 265 across the 6 observational. Of the 16 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Cairo University is the lead sponsor of 4,956 studies on the registry; 1,466 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
3 of the studies in Multiple Sclerosis by Cairo University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07943247Cairo UniversityCorrelation Between Physical Activity and Pulmonary Endurance in MS Patients | 2027-02-01 |
| NCT07918339Cairo UniversityVirtual Reality Versus Mental Practice On Balance And Gait In Patients With Multiple Sclerosis | 2027-03-15 |
| NCT07762326Cairo UniversityEffect of Artificial Intelligence Based Cognitive Training on Sleep Disorders and Quality of Life in Patients With Multiple Sclerosis | 2027-03-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 26 studies in Multiple Sclerosis by Cairo University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Multiple sclerosis (MS) is a chronic neurological disease that can affect movement, muscle strength, physical activity, and breathing. Individuals with MS may experience reduced physical activity and changes in pulmonary function, even during the early stages of the disease. However, the relationship between physical activity levels and pulmonary function in individuals with MS remains insufficiently understood. This observational study aims to investigate whether physical activity levels are associated with pulmonary function in adults with multiple sclerosis. A total of 94 participants with a confirmed diagnosis of MS are expected to be recruited. Physical activity will be assessed using the Arabic version of the International Physical Activity Questionnaire-Short Form (IPAQ-SF), while pulmonary function will be evaluated using spirometry. The study will examine whether individuals with different levels of physical activity also demonstrate differences in pulmonary function. The findings may help improve understanding of physical and respiratory health in individuals with MS and inform future rehabilitation assessment and management strategies.
Multiple sclerosis (MS) is a chronic immune-mediated inflammatory and neurodegenerative disorder of the central nervous system characterized by demyelination, axonal injury, and progressive neurological dysfunction. Individuals with MS may experience muscle weakness, fatigue, impaired mobility, reduced physical activity, and respiratory dysfunction. Reduced habitual physical activity may contribute to generalized physical deconditioning, whereas impaired pulmonary function may be associated with reduced exercise tolerance and limitations in daily physical activities. Although previous research has investigated physical activity and respiratory impairments in individuals with MS, evidence regarding the direct association between habitual physical activity and spirometric pulmonary function remains limited. Therefore, this study aims to investigate the correlation between physical activity and pulmonary function in individuals with multiple sclerosis.
This study will employ an observational, cross-sectional design involving a target sample of 94 adults with neurologist-confirmed multiple sclerosis recruited from neurology outpatient clinics and physical therapy departments in Egypt. Following eligibility screening and written informed consent, participants will undergo a single assessment session. Demographic and relevant clinical information will be collected, including disease characteristics, medication history, smoking status, and neurological disability assessed using the Expanded Disability Status Scale (EDSS). Habitual physical activity during the preceding seven days will be assessed using the Arabic version of the International Physical Activity Questionnaire-Short Form (IPAQ-SF), which provides estimates of physical activity expressed in metabolic equivalent minutes per week (MET-min/week). Pulmonary function will be assessed using a calibrated computerized spirometer following standardized American Thoracic Society/European Respiratory Society (ATS/ERS) procedures. The relationship between physical activity and pulmonary function will be investigated using correlation-based statistical analysis. The study will test the null hypothesis that no association exists between physical activity and pulmonary function in individuals with MS. As this is a cross-sectional observational study, the findings will be interpreted as associations rather than evidence of causation. No therapeutic intervention will be administered as part of the study. The results may contribute to a better understanding of the relationship between habitual physical activity and respiratory function in MS and provide information relevant to future rehabilitation research and clinical assessment.
Adults with neurologist-confirmed MS will be screened for eligibility. The diagnosis, MS phenotype, disease duration, current disease-modifying therapy, recent relapse history, and relevant comorbidity will be verified from the medical record where available.
**Inclusion Criteria:**
Are aged 20-40 years.
Are clinically stable at the time of assessment.
18-29.
Have experienced no acute MS relapse or systemic treatment during the preceding 30 days.
Mini-mental status score > 24.
Can understand and follow the assessment instructions.
Can perform acceptable spirometry maneuvers.
Can complete the physical activity questionnaire independently or with standardized clarification from the assessor.
Provide written .
**Exclusion Criteria:**
A diagnosed pulmonary disorder likely to affect spirometry independently, including , uncontrolled asthma, bronchiectasis, interstitial lung disease, or a history of major pulmonary surgery.
An acute respiratory tract infection during the preceding four weeks.
Unstable or cardiovascular disease that contraindicates maximal expiratory efforts or physical assessment.
A neurological disorder other than MS that may independently affect muscle strength, muscle quantity, physical activity, or pulmonary function.
A major musculoskeletal disorder, recent fracture, recent orthopedic surgery, or lower-limb injury that interferes with usual physical activity.
Pregnancy.
Cognitive, communication, or behavioral impairment that prevents valid completion of the assessment.
Any to spirometry according to ATS/ERS recommendations (Graham et al., 2019).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Correlation Between Physical Activity and Forced Vital Capacity (FVC) in Individuals with Multiple Sclerosis
The primary outcome will be the correlation between total self-reported physical activity and forced vital capacity (FVC) in individuals with multiple sclerosis. Physical activity will be assessed using the Arabic version of the International Physical Activity Questionnaire-Short Form (IPAQ-SF), with total physical activity expressed in metabolic equivalent minutes per week (MET-min/week). FVC will be measured in liters using standardized computerized spirometry according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines. The association between total physical activity and FVC will be evaluated using correlation analysis.
Time frame: At a single study visit (Day 1); physical activity will be assessed for the preceding 7 days.
No study locations are listed for this record.
Start is estimated for Dec 2026; primary completion for Feb 2027, 2 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.